GTG Bio to Participate in "CPHI China 2026"

"Establishing Global Partnerships Based on InnoLAMP"

On June 16, GTG Bio announced that it will participate in "CPHI China 2026," the largest pharmaceutical and biotech industry exhibition in Asia, held in Shanghai, China until June 18 (local time), as part of its efforts to expand into the global market.

At this event, GTG Bio will showcase its proprietary drug delivery system (DDS) platform, "InnoLAMP," as well as the research and development (R&D) achievements of its major pipeline candidates.

The exterior view of GTG Bio company in Cheongju, Chungbuk. GTG Bio

GTG Bio will release one-month pharmacokinetic (PK) data for cagrilintide, tirzepatide, and retatrutide—dual and triple agonists with high dosages that present challenges for one-month formulation development—and will demonstrate the potential for subcutaneous (SC) formulations through its high drug loading technology.

During CPHI China, the company plans to conduct one-on-one business meetings with multiple global pharmaceutical companies, biotech firms, and investment institutions, focusing on expanding global agreements such as technology licensing (L/O), joint R&D, and global co-commercialization deals.

GTG Bio aims to use this exhibition as a bridgehead to expand its influence in the rapidly growing Chinese and Asian markets, as well as to strengthen networks with partners in advanced markets such as North America and Europe, with the goal of achieving concrete results in overseas expansion at an early stage.

A representative from GTG Bio stated, "CPHI China is a key platform where the most active and substantive business deals are discussed in the global pharmaceutical and biotech market. We will prove the commercial value of our differentiated InnoLAMP platform and accelerate the enhancement of our corporate value and global market expansion through the attraction of multifaceted strategic partnerships."

This content was produced with the assistance of AI translation services.